KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Operating Income: 2019-2024

Historic Operating Income for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to -$479.0 million.

  • Recursion Pharmaceuticals' Operating Income fell 75.08% to -$172.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$723.6 million, marking a year-over-year decrease of 83.57%. This contributed to the annual value of -$479.0 million for FY2024, which is 36.83% down from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Operating Income stood at -$479.0 million for FY2024, which was down 36.83% from -$350.1 million recorded in FY2023.
  • Over the past 5 years, Recursion Pharmaceuticals' Operating Income peaked at -$84.6 million during FY2020, and registered a low of -$479.0 million during FY2024.
  • In the last 3 years, Recursion Pharmaceuticals' Operating Income had a median value of -$350.1 million in 2023 and averaged -$358.3 million.
  • Data for Recursion Pharmaceuticals' Operating Income shows a maximum YoY plummeted of 116.01% (in 2021) over the last 5 years.
  • Recursion Pharmaceuticals' Operating Income (Yearly) stood at -$84.6 million in 2020, then slumped by 116.01% to -$182.8 million in 2021, then slumped by 34.44% to -$245.7 million in 2022, then plummeted by 42.46% to -$350.1 million in 2023, then crashed by 36.83% to -$479.0 million in 2024.